

# Russell D Cohen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5322224/russell-d-cohen-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100  
papers

4,986  
citations

32  
h-index

70  
g-index

105  
ext. papers

5,775  
ext. citations

3.4  
avg, IF

5.46  
L-index

#	Paper	IF	Citations
100	Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.. <i>Intestinal Research</i> , <b>2022</b> ,	4.1	1
99	Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis.. <i>Digestive Diseases and Sciences</i> , <b>2022</b> , 67, 805	4	
98	Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1008-1016	4.5	1
97	Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1620-1625	4.5	3
96	Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 2785-2793	4	0
95	Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 236-241	4.5	7
94	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 104-110	6.9	21
93	Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. <i>Gastroenterology</i> , <b>2021</b> , 160, 1131-1139	13.3	36
92	The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. <i>Digestion</i> , <b>2021</b> , 102, 767-775	3.6	4
91	Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1365-1372	6.1	3
90	A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis. <i>Gastroenterology and Hepatology</i> , <b>2020</b> , 16, 21-27	0.7	
89	Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 637-643	6.1	15
88	Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 559-560	6.1	1
87	The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 192-204	1.5	23
86	Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 2090-2095	4	4
85	Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3596-3601	4	25
84	Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 1158-1162	1.5	162 <sup>18</sup>

83	Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. <i>Gastrointestinal Endoscopy</i> , <b>2019</b> , 90, 269-275	5.2	12
82	Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 1105-1110	1.5	17
81	Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 205-206	6.9	11
80	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 486-493	6.9	53
79	Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. <i>Diseases of the Colon and Rectum</i> , <b>2019</b> , 62, 463-469	3.1	7
78	Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti- $\alpha$ -CTLA4 and anti-PD1 antibodies <b>2019</b> , 7, 1		75
77	Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 1294-1301	4	44
76	Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 490-501	4.5	53
75	The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 502-509	4.5	28
74	Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 1016-1024	4	7
73	Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , <b>2018</b> , 87, 1304-1309	5.2	16
72	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 849-860	4.5	24
71	Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 1291-1297	4.5	2
70	Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 99-105	6.9	63
69	A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 933-940	6.1	8
68	Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. <i>Journal of Clinical Gastroenterology</i> , <b>2018</b> , 52, 537-544	3	17
67	Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 785-791	1.5	40
66	Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182900	3.7	28

65	Nonmedical Switching of Biosimilars in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , <b>2017</b> , 13, 697-699	0.7	
64	Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. <i>American Journal of Clinical Nutrition</i> , <b>2016</b> , 104, 113-20	7	57
63	Approach to Optimize Anti-TNF- $\alpha$ Therapy in Patients With IBD. <i>Current Treatment Options in Gastroenterology</i> , <b>2016</b> , 14, 83-90	2.5	12
62	The Effect of Maternal Peripartum Anti-TNF- $\alpha$ Use on Infant Immune Response. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 1622-7	4	29
61	Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1027-31	4.5	17
60	Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 631-7	4.5	19
59	Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1919-25	6.9	15
58	Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. <i>Journal of Medical Economics</i> , <b>2015</b> , 18, 447-56	2.4	32
57	Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 1719-36	4.5	25
56	What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. <i>Gastroenterology and Hepatology</i> , <b>2015</b> , 11, 657-65	0.7	8
55	Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1722-8	4.5	9
54	The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 2778-86	4.5	17
53	Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 2577-83	4.5	22
52	Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 621-6	4.5	30
51	P-074 Age of Diagnosis Is Associated with the Severity of Adverse Effects to Therapy in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, S55	4.5	1
50	Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 10-6	4.5	25
49	Assessment of variables associated with smoking cessation in Crohn's disease. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1026-32	4	11
48	Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1409-22	0.7	513

47	Direct and Indirect Utilization and Costs Associated With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, S41	4.5	
46	Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. <i>Drug Design, Development and Therapy</i> , <b>2011</b> , 5, 111-6	4.4	5
45	How should we treat severe acute steroid-refractory ulcerative colitis?. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 150-1	4.5	5
44	Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1302-7	4.5	90
43	Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. <i>Journal of Clinical Gastroenterology</i> , <b>2009</b> , 43, 613-6	3	123
42	Response:. <i>Gastrointestinal Endoscopy</i> , <b>2008</b> , 67, 1009-1010	5.2	1
41	Optimizing conventional therapy for inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , <b>2008</b> , 10, 585-90	5	22
40	Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 738-43	4.5	98
39	Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 1707-14	4.5	34
38	Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?. <i>Gastrointestinal Endoscopy</i> , <b>2007</b> , 65, 998-1004	5.2	204
37	Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. <i>Current Treatment Options in Gastroenterology</i> , <b>2007</b> , 10, 185-94	2.5	12
36	Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2007</b> , 1, 101-12	4.2	5
35	Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. <i>Therapeutics and Clinical Risk Management</i> , <b>2007</b> , 3, 919-27	2.9	7
34	Management of refractory ulcerative colitis. <i>Current Treatment Options in Gastroenterology</i> , <b>2006</b> , 9, 234-45	2.5	2
33	Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. <i>Current Medical Research and Opinion</i> , <b>2006</b> , 22, 989-1000	2.5	76
32	Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 621-30	6.9	724
31	Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. <i>Journal of Clinical Gastroenterology</i> , <b>2006</b> , 40, 669-77	3	67
30	Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. <i>Inflammatory Bowel Diseases</i> , <b>2006</b> , 12, 979-94	4.5	77

29	Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. <i>Inflammatory Bowel Diseases</i> , <b>2006</b> , 12, 972-8	4.5	53
28	Mesalamine delivery systems: do they really make much difference?. <i>Advanced Drug Delivery Reviews</i> , <b>2005</b> , 57, 281-302	18.5	65
27	Postoperative management of ulcerative colitis and Crohn's disease. <i>Current Gastroenterology Reports</i> , <b>2005</b> , 7, 492-9	5	5
26	An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 1984-9	0.7	221
25	Medical therapy for ulcerative colitis: the state of the art and beyond. <i>Current Gastroenterology Reports</i> , <b>2004</b> , 6, 488-95	5	16
24	Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. <i>Drugs</i> , <b>2004</b> , 64, 1767-77	12.1	57
23	Collagenous gastritis: an unusual association with profound weight loss. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2004</b> , 128, 229-32	5	15
22	IBD: the drugs work...but do the patients?. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, 722-3	0.7	4
21	First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. <i>Journal of Clinical Apheresis</i> , <b>2002</b> , 17, 204-6	3.2	11
20	Evolving medical therapies for ulcerative colitis. <i>Current Gastroenterology Reports</i> , <b>2002</b> , 4, 497-505	5	12
19	Infliximab as first-line therapy for severe Crohn's disease?. <i>Inflammatory Bowel Diseases</i> , <b>2002</b> , 8, 58-9; discussion 63-5	4.5	1
18	Crohn's disease and Takayasu's arteritis. <i>Journal of Clinical Gastroenterology</i> , <b>2002</b> , 34, 454-6	3	19
17	Infliximab decreases resource use among patients with Crohn's disease. <i>Journal of Clinical Gastroenterology</i> , <b>2002</b> , 35, 151-6	3	96
16	Evolving medical therapies for ulcerative colitis. <i>Current Gastroenterology Reports</i> , <b>2001</b> , 3, 464-70	5	1
15	Transcending therapeutic conventions: New realities in the treatment of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2001</b> , 7, S1-S1	4.5	
14	Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. <i>Inflammatory Bowel Diseases</i> , <b>2001</b> , 7 Suppl 1, S17-22	4.5	40
13	Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 2929-33	0.7	342
12	Side-to-side isoperistaltic stricturoplasty in extensive Crohn's disease: a prospective longitudinal study. <i>Annals of Surgery</i> , <b>2000</b> , 232, 401-8	7.8	77

11	A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 1263-76	0.7	195
10	Infliximab in Crohn's disease: first anniversary clinical experience. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 3469-77	0.7	173
9	The cost of hospitalization in Crohn's disease. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 524-30	0.7	120
8	Infliximab decreases resource utilization in patients with Crohn's disease. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 2499-2500	0.7	4
7	Intravenous cyclosporin in ulcerative colitis: a five-year experience. <i>American Journal of Gastroenterology</i> , <b>1999</b> , 94, 1587-92	0.7	250
6	A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. <i>Inflammatory Bowel Diseases</i> , <b>1999</b> , 5, 1-10	4.5	58
5	Advances in the management of Crohn's disease: economic and clinical potential of infliximab. <i>Clinical Therapeutics</i> , <b>1998</b> , 20, 1009-28	3.5	46
4	UC CANCERS IN PSC: RIGHT SIDED OR WRONG?. <i>Inflammatory Bowel Diseases</i> , <b>1998</b> , 4, 330	4.5	
3	Nicotine in Ulcerative Colitis. <i>BioDrugs</i> , <b>1996</b> , 5, 169-174		21
2	Immunomodulatory agents and other medical therapies in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , <b>1995</b> , 11, 321-330	3	10
1	Correlation of nuclear morphometry and DNA ploidy in rectal cancer. <i>Diseases of the Colon and Rectum</i> , <b>1991</b> , 34, 449-54	3.1	13